TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Publications: details revised at 4 of 4 entriesv13
  2. Re-verified, no change to tracked fieldsv12
  3. Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Mar 2014 to May 2014
    v11
  4. 2 versions Re-verified since Sep 4, 2013, no change to tracked fieldsv9-v10
  5. Primary completion date: Mar 2014 to Mar 2011v8 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 120 to confirmed 77
    • Study completion date: Mar 2014
    • Site details revised
Show 6 earlier versionsHide 6 earlier versions
  1. Re-verified, no change to tracked fieldsv7
  2. Enrollment target: 206 to 120
    • Primary completion date: Mar 2014
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study arms: 0 to 2
    v6
  3. 2 versions Re-verified since Apr 26, 2007, no change to tracked fieldsv4-v5
  4. Start date: Apr 2004v3
  5. Interventions: ciclosporine (Drug), rapamycine (Drug), tacrolimus (Drug) to ciclosporine (Drug), rapamycin (Drug), tacrolimus (Drug)v2 Show 4 more changesShow less
    • Secondary endpoints revised (3)
    • Primary endpoint revised
    • Study title expanded, about 13 words
    • Eligibility criteria expanded, about 5 words
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin as compared to patients who are maintained under calcineurin inhibitors.
Trial Details
NCT Number NCT00133887
Lead Sponsor Hospices Civils de Lyon
Conditions
(from sponsor)		 Skin Cancer, Kidney Transplantation
Related terms Carcinoma, Squamous Cell, Skin Neoplasms
Enrollment 77 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov